Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation.

Xu Y, Thall PF, Hua W, Andersson BS.

J R Stat Soc Ser C Appl Stat. 2019 Apr;68(3):809-828. doi: 10.1111/rssc.12331. Epub 2018 Dec 16.

PMID:
31467455
2.

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.

Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR.

Haematologica. 2019 Dec;104(12):e555-e557. doi: 10.3324/haematol.2018.214429. Epub 2019 Apr 4. No abstract available.

3.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH.

Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

PMID:
30910541
4.

Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses.

Kawedia JD, Kalariya N, Gulbis AM, Andersson BS, Myers AL.

Clin J Oncol Nurs. 2019 Apr 1;23(2):191-196. doi: 10.1188/19.CJON.191-196.

PMID:
30880803
5.

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS.

Bone Marrow Transplant. 2019 Aug;54(8):1245-1253. doi: 10.1038/s41409-018-0405-0. Epub 2018 Dec 10.

PMID:
30532055
6.

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS.

Lancet Haematol. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X.

7.

Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.

Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO.

Bone Marrow Transplant. 2019 Jun;54(6):839-848. doi: 10.1038/s41409-018-0344-9. Epub 2018 Sep 26.

PMID:
30258129
8.

Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.

Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS.

Exp Hematol. 2018 Nov;67:49-59.e1. doi: 10.1016/j.exphem.2018.08.002. Epub 2018 Aug 10.

9.

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2.

10.

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.

Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1514-1520. doi: 10.1016/j.bbmt.2018.02.003. Epub 2018 Feb 12.

11.

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Oncotarget. 2017 Dec 17;9(3):3908-3921. doi: 10.18632/oncotarget.23386. eCollection 2018 Jan 9.

12.

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.

Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K.

Blood. 2018 Mar 15;131(11):1248-1257. doi: 10.1182/blood-2017-07-798751. Epub 2018 Jan 31.

13.

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.

Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2018 May;24(5):1079-1087. doi: 10.1016/j.bbmt.2018.01.001. Epub 2018 Jan 8.

14.

Viral-specific T-cell response in hemorrhagic cystitis after haploidentical donor stem cell transplantation.

Apiwattanakul N, Hongeng S, Anurathapan U, Pakakasama S, Srisala S, Techasaensiri C, Andersson BS.

Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12775. Epub 2017 Oct 25.

PMID:
28865164
15.

Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS.

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):901-923. doi: 10.1080/17425255.2017.1360277. Epub 2017 Aug 17. Review.

16.

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M.

Lancet Haematol. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15.

17.

Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.

Valdez BC, Hassan M, Andersson BS.

Exp Hematol. 2017 Aug;52:65-71. doi: 10.1016/j.exphem.2017.04.011. Epub 2017 May 4.

18.

The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Leuk Lymphoma. 2017 Nov;58(11):2705-2716. doi: 10.1080/10428194.2017.1306647. Epub 2017 Apr 10.

19.

Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott-Aldrich syndrome.

Kreetapirom P, Hongeng S, Manuyakorn W, Anurathapan U, Pakakasama S, Sirachainan N, Andersson BS.

Bone Marrow Transplant. 2017 Jun;52(6):913-914. doi: 10.1038/bmt.2017.25. Epub 2017 Mar 13. No abstract available.

PMID:
28287640
20.

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.

Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO.

Am J Hematol. 2017 Apr;92(4):331-337. doi: 10.1002/ajh.24632. Epub 2017 Feb 13.

21.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L.

Blood. 2017 Mar 9;129(10):1389-1393. doi: 10.1182/blood-2016-09-737825. Epub 2017 Jan 3.

22.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

23.

Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.

Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K.

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12632. Epub 2016 Dec 28.

PMID:
27862740
24.

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2017 Feb;23(2):285-292. doi: 10.1016/j.bbmt.2016.11.001. Epub 2016 Nov 2.

25.

Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.

Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Oncotarget. 2016 Sep 27;7(39):63829-63838. doi: 10.18632/oncotarget.11561.

26.

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.

Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE.

Haematologica. 2017 Jan;102(1):110-117. doi: 10.3324/haematol.2016.144253. Epub 2016 Aug 18.

27.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

28.

Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.

Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Leuk Res. 2016 Aug;47:100-8. doi: 10.1016/j.leukres.2016.05.019. Epub 2016 May 27.

29.

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Cancer. 2016 Sep 1;122(17):2680-8. doi: 10.1002/cncr.30100. Epub 2016 May 20.

30.

Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?

Andersson BS, Valdez BC.

Bone Marrow Transplant. 2016 Jul;51(7):919-20. doi: 10.1038/bmt.2016.110. Epub 2016 Apr 25. No abstract available.

PMID:
27111045
31.

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1218-1226. doi: 10.1016/j.bbmt.2016.03.027. Epub 2016 Apr 4.

32.

Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.

Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Leuk Lymphoma. 2016 Nov;57(11):2644-52. doi: 10.3109/10428194.2016.1157871. Epub 2016 Mar 16.

PMID:
26980288
33.

Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.

Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS.

Exp Hematol. 2016 Jun;44(6):458-65. doi: 10.1016/j.exphem.2016.03.001. Epub 2016 Mar 11.

34.

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.

Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U.

Biol Blood Marrow Transplant. 2016 May;22(5):961-5. doi: 10.1016/j.bbmt.2016.02.008. Epub 2016 Feb 26.

35.

Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.

Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Rujkijyanont P, Meekaewkunchorn A, Lektrakul Y, Iamsirirak P, Surapolchai P, Satayasai W, Sirireung S, Sruamsiri R, Wahidiyat PA, Ungkanont A, Issaragrisil S, Andersson BS.

Bone Marrow Transplant. 2016 Jun;51(6):813-8. doi: 10.1038/bmt.2016.7. Epub 2016 Feb 15.

37.

Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients.

Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K.

Am J Transplant. 2016 May;16(5):1492-502. doi: 10.1111/ajt.13635. Epub 2016 Mar 2.

38.

Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.

Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML.

J Natl Cancer Inst. 2015 Nov 18;108(3). pii: djv342. doi: 10.1093/jnci/djv342. Print 2016 Mar. Review.

39.

Romidepsin targets multiple survival signaling pathways in malignant T cells.

Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS.

Blood Cancer J. 2015 Oct 16;5:e357. doi: 10.1038/bcj.2015.83.

40.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2016 Jan;22(1):47-53. doi: 10.1016/j.bbmt.2015.08.031. Epub 2015 Sep 4.

41.

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1948-54. doi: 10.1016/j.bbmt.2015.07.005. Epub 2015 Jul 14.

42.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1914-20. doi: 10.1016/j.bbmt.2015.06.003. Epub 2015 Jun 11.

43.

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.

Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ.

Blood. 2015 May 7;125(19):2885-92. doi: 10.1182/blood-2015-01-607366. Epub 2015 Mar 16.

44.

Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.

Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS.

Exp Hematol. 2015 Jun;43(6):448-61.e2. doi: 10.1016/j.exphem.2015.02.001. Epub 2015 Feb 19.

45.

Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?

Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2015 Apr;21(4):713-9. doi: 10.1016/j.bbmt.2014.12.018. Epub 2014 Dec 23.

46.

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L.

J Clin Oncol. 2014 Nov 1;32(31):3497-505. doi: 10.1200/JCO.2013.54.0625. Epub 2014 Sep 29.

47.

Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.

Song G, Valdez BC, Li Y, Liu Y, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1687-95. doi: 10.1016/j.bbmt.2014.08.003. Epub 2014 Aug 9.

48.

Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.

Anurathapan U, Pakakasama S, Mekjaruskul P, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Pongtanakul B, Rujkijyanont P, Meekaewkunchorn A, Sruamsiri R, Ungkanont A, Issaragrisil S, Andersson BS, Hongeng S.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2066-71. doi: 10.1016/j.bbmt.2014.07.016. Epub 2014 Jul 23.

49.

Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.

Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1139-44. doi: 10.1016/j.bbmt.2014.04.003. Epub 2014 Apr 13.

50.

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.

Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS.

Blood Cancer J. 2014 Jan 10;4:e171. doi: 10.1038/bcj.2013.69.

Supplemental Content

Loading ...
Support Center